The usually recognized curative option for secondary leukemia includes chemotherapy followed by hematopoietic SCT (HSCT). 3, 4 A significant proportion of women with leukemia after breast cancer treatment experience diseasefree survival after HSCT similar to that of patients with de novo leukemia, and no patient with relapsed breast cancer is reported. 4 We reported on two cases of women who achieved AML CR before HSCT, but associated with a rapid relapse of breast cancer.
In May 2005, a 39-year-old woman presented with right breast cancer: pT1pN0M0 RHÀ CERB2À SBR III infiltrating ductular carcinoma. She was treated with surgery (lumpectomy and axillary lymph node surgery), FEC 100 adjuvant chemotherapy (6 cycles: 5 fluoro-uracil 500 mg/m 2 , epirubicin 100 mg/m 2 and CY 500 mg/m 2 ) and local radiotherapy. In January 2008, she was referred to our unit for AML type 2 with abnormal karyotype (t(8;21)) and AML1-ETO rearrangement. Induction chemotherapy in- . Neutrophil engraftment was achieved at day 21. On day 25, she presented liver abnormalities and a depressed level of consciousness. She was intubated and ventilated. At this date, PCR of HHV6 was positive and treated with ganciclovir. One month later (day 34), moderate digestive GVHD occurred, requiring immunosuppression with methylprednisolone. On day 38, she presented fever and right pneumonia. On day 49, EF was of about 45%, with grade 2 tricuspid regurgitation and a non-dilated right ventricle. On day 56, she died of multiorgan failure.
The second case is a 44-year-old woman who was diagnosed with left pT1pN3M0 RE þ RP þ CERB2 þ þ þ SBR III infiltrating ductular carcinoma in August 2007 and treated with surgery (lumpectomy and axillary lymph node surgery), adjuvant chemotherapy (6 cycles: docetaxel 75 mg/m 2 , doxorubicin 50 mg/m 2 and CY 500 mg/m 2 ) and radiotherapy (local and axillary nodes). She received herceptin and lapatinib for 1 year (ALTTO protocol) with tamoxifen. In September 2009, she presented a secondary acute AML with abnormal karyotype (t (11;19) ). Induction chemotherapy included DNR 60 mg/m 2 and aracytine 200 mg/m 2 (3 þ 7). She received cardioxane for protection against the cardiotoxicity of anthracyclines. She was in CR after induction chemotherapy. Consolidation chemotherapy included high-dose aracytine. In January 2010, she underwent allo-SCT from an HLA-identical sibling donor. At transplant, she was in CR for both acute leukemia and breast cancer. Myeloablative conditioning consisted of BU (4 days) and melphalan (140 mg/m 2 ). GVHD prophylaxis was provided with i.v. MTX and i.v. CYA. Neutrophil engraftment was achieved at day 11. She developed no acute GVHD. On day 24, she presented fever and interstitial pneumonia. The computed tomography scan showed pulmonary bilateral interstitial infiltrates with micronodules. PCR of HHV6 was positive and was treated with ganciclovir. Throughout treatment, the left ventricular ejection fraction (EF) was also assessed by biplanar crosssectional echocardiography. In August 2009, EF was about 80%. On day À2, she presented left heart failure with tachycardia. Despite nebivolol introduction, the patient's condition deteriorated. On day 12, echocardiography revealed a dilated hypokinetic left ventricle with an EF of about 50%. We introduced ramipril and furosemide. On day 26, EF was about 42% with a dilated hypokinetic left ventricle and grade 2 mitral regurgitation (cf. Figure 1) . Despite an anti-infectious treatment combined with cardiac treatment, the pulmonary status deteriorated. On day 30, she had a bronchoalveolar lavage. On day 31, the patient developed acute respiratory failure with severe hypoxemia, deteriorating rapidly despite intensive supportive therapies, and she died of cardiac arrest. Analysis of the bronchoalveolar lavage resulted in positive detection of carcinomatosis cells. Microbiological tests for bacteria, virus and fungus detection were negative.
In both cases, the clinical presentation was compatible with heart failure. Anthracyclines are widely used for breast cancer and despite cardiotoxicity; treatment of secondary leukemia usually requires additional courses of anthracycline-based chemotherapy. Most patients develop transient or definitive cardiac dysfunction and both patients presented with cardiac dysfunction during allogeneic transplantation. 5 In our cases, evaluation before allo-SCT was good and in the second case, cardioxane was administered in induction to limit the cardiotoxicity of anthracyclines. In both relapses, clinical manifestations were similar, such as cardiac dysfunction, in particular with bilateral infiltration in the chest X radiography. Allo-SCT was applied for metastatic breast cancer. Allo-SCT enables the attainment of prolonged disease control attributable to a graftvs-tumor effect. 6 The routine application of non-myeloablative transplantation for metastatic breast cancer may lead to a small benefit in PFS, but all patients reported ultimately died. 7 The benefit is predominant for tumors with a good response before SCT. 8 In our cases, the patients received anthracycline in induction and conditioning was myeloablative, which can decrease the risk of relapse. Despite these conditions, the graft versus tumor (GVT) effect suggested was not efficient. In the results of Blaise et al., it is discussed that a high initial level of immunosuppression could contribute to a lack of response in patients with renal cell carcinoma. In our two patients, progression was rapid after SCT. It cannot be excluded that not only were GVT not present but also that the initial high level of immunosuppression contributed to or accelerated progression.
